<DOC>
	<DOCNO>NCT01012219</DOCNO>
	<brief_summary>This 3-period study . Periods 1 2 evaluate effect multiple dos laropiprant antiplatelet effect clopidogrel aspirin administer combination participant primary hypercholesterolemia mixed dyslipidemia . Period 3 open-label evaluate single dose pharmacokinetics nicotinic acid laropiprant component Tredaptive .</brief_summary>
	<brief_title>A Study Evaluate Effects Laropiprant Antiplatelet Effects Clopidogrel Aspirin Combination ( MK-0524A-114 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>Participant primary hypercholesterolemia mixed dyslipidemia ( high cholesterol ) Participant nonsmoker Participant history chronic seizure Participant history cancer Participant history stomach intestinal ulcer history GI bleeding Participant major surgery , donate blood participate another investigational study past 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>